Actos

Type: Product
Name: Actos
First reported 21 hours ago - Updated 21 hours ago - 1 reports

Bid Now - P&G Europe Q3: Surplus Production And Packaging Equipment

This event is now open for bidding. To place a bid or find out more, visit international.go-dove.com/event-18882 .An online auction for company lorry, climate test chamber, surface grinding machine, injection moulding machines, packing machine, milling ... [Published GoIndustry Dovebid - 21 hours ago]
First reported Sep 16 2014 - Updated Sep 16 2014 - 1 reports

Behind the Great Firewall Of Ediscovery In Asia

When dealing with US requests for data subject to ediscovery rules in Asia, corporate counsel at multinational corporations must be on top of their game. Managing ediscovery in the United States alone presents a significant set of challenges; however, ... [Published JD Supra - Sep 16 2014]
First reported Sep 16 2014 - Updated Sep 16 2014 - 1 reports

New COO engineers a management shake-up at Takeda

Takeda didn't bring on non-Japanese COO Christophe Weber for nothing. The Osaka-based drugmaker, still faltering in the wake of its patent loss on diabetes champ Actos, was looking for a shake-up.And now, as promised, the blueprints for a new, reorganized ... [Published FiercePharma - Sep 16 2014]
First reported Sep 05 2014 - Updated Sep 05 2014 - 1 reports

Court Denies Lilly, Takeda’s Request to Toss $9 Billion Damage Award in Bladder Cancer Case

Eli Lilly and Takeda Pharmaceuticals have lost their appeal to reverse a combined jury award of $9 billion in punitive damages for hiding bladder cancer risks associated with their diabetes drug Actos, but experts say that verdict will likely be r ... [Published FDA News - Sep 05 2014]
First reported Sep 03 2014 - Updated Sep 04 2014 - 4 reports

Takeda Pharmaceutical : U.S. court orders Takeda to pay $6 billion over Actos diabetes drug

Takeda Pharmaceutical Co. said Thursday it has been ordered by a U.S. district court to pay $6 billion in punitive damages over a lawsuit filed by a man who claimed his bladder cancer was caused by Takeda's diabetes medicine Actos.The ruling is in line ... [Published 4 Traders - Sep 04 2014]
First reported Sep 03 2014 - Updated Sep 03 2014 - 1 reports

Mealey's PI/Product Liability - Actos MDL Judge Denies JMOL In $9B Bladder Cancer Verdict, Citing All Evidence

LAFAYETTE, La. - Takeda Pharmaceutical Co. Ltd. and Eli Lilly & Co. were denied judgment as a matter of law on Aug. 28 in the first federal Actos bladder cancer trial that resulted in a $9 billion verdict (In Re: Actos [Pioglitazone] Products Liability ... [Published Mealey - Sep 03 2014]
First reported Sep 01 2014 - Updated Sep 01 2014 - 4 reports

Takeda to submit data for pioglitazone containing medicines including ACTOS

Takeda Pharmaceutical Company Limited announced the completion of the post-marketing commitment and submissions of data from a 10-year epidemiology study to regulatory authorities including the United States (U.S.) Food and Drug Administration (FDA), ... [Published Hospital Pharmacy Europe - Sep 01 2014]
First reported Aug 31 2014 - Updated Aug 31 2014 - 2 reports

Actos Lawsuit News: Federal Judge Won’t Dismiss $9 Billion Verdict in...

The Firm is evaluating Actos lawsuits on behalf of individuals who developed bladder cancer, allegedly due to long-term use of the Type 2 diabetes drug. The federal judge overseeing thousands of Actos bladder cancer lawsuits (http://www.theactoslawsuitcenter.com/) ... [Published PRWeb - Aug 31 2014]
First reported Aug 28 2014 - Updated Aug 29 2014 - 15 reports

Takeda fails to overturn USD9 billion award for Actos cancer cover up

Takeda, manufacturers of the drug, Actos, have failed to overturn the award of $9 billion for covering up risks of bladder cancer associated with the drug.Takeda and marketing partner Lilly were charged with $9 billion punitive charges in April this year ... [Published Diabetes.co.uk - Aug 29 2014]
First reported Aug 29 2014 - Updated Aug 29 2014 - 2 reports

No Actos Cancer Link in Long Term Data

Related Biotechnology, Pharmaceutical and Healthcare News(MedPage Today) -- Topline results from a 10-year analysis of diabetic patients treated with pioglitazone (Actos) indicated no increased risk of bladder cancer, even with long-term use, the drug's ... [Published BioPortfolio - Aug 29 2014]
First reported Aug 27 2014 - Updated Aug 29 2014 - 2 reports

Takeda Announces Completion of the Post-Marketing Commitment to Submit Data to the FDA, the EMA and the PMDA for Pioglitazone Containing Medicines Including ACTOS

OSAKA, Japan, Aug. 28, 2014 /PRNewswire/ -- Takeda Pharmaceutical Company Limited ("Takeda") today announced the completion of the post-marketing commitment and submissions of data from a 10-year epidemiology study to regulatory authorities including ... [Published PR Newswire: Health - Aug 28 2014]
First reported Aug 29 2014 - Updated Aug 29 2014 - 1 reports

Judge Rejects Challenge to $9 Billion Actos Verdict

A federal judge on Thursday refused to toss out a $9 billion verdict in the first federal bellwether trial over claims that taking Actos increased the risk of getting bladder cancer. ... [Published Law.com - Newswire - Aug 29 2014]

Quotes

...rang of recent moves from Takeda's pharma peers, many of which have recently shed their non-core assets to double down on core areas of focus. "Our aspiration for Takeda is to be the best-in-class company in every aspect of our business" he said in a statement
...significantly reduced punitive damage award," said Kenneth D Greisman , senior vice president and general counsel, Takeda Pharmaceuticals U S A Inc. "The ruling on that motion is expected in the coming weeks."
To Neas, it's a "clarion call" to lawmakers and regulators to keep the copies coming. "We must work together to sustain the success of generics today and pave the way for safe, affordable biologic therapies tomorrow" he said in a statement
...December 9th, 2014, Reed Smith partner Barbara Binis and Jennifer Dubas, Vice President of Litigation & Risk at Endo Pharmaceuticals, will present "Strategically Addressing Alarming Trends in Drug and Med Litigation: Third Party Funding of Claims and Subrogation Actions By Health Insurers" at the

More Content

All (177) | News (135) | Reports (0) | Blogs (40) | Audio/Video (0) | Fact Sheets (1) | Press Releases (1)
sort by: Date | Relevance
Armed with 900 reps, Takeda aims for the Contra... [Published FiercePharma - 16 hours ago]
Bid Now - P&G Europe Q3: Surplus Production And... [Published GoIndustry Dovebid - 21 hours ago]
Behind the Great Firewall Of Ediscovery In Asia [Published JD Supra - Sep 16 2014]
New COO engineers a management shake-up at Takeda [Published FiercePharma - Sep 16 2014]
A Foregone Conclusion On A Runaway Verdict [Published Drug and Device Law - Sep 12 2014]
Oramed’s Insulin Pill Superior to New Diabetes ... [Published BioMedReports - Sep 11 2014]
Takeda Pharmaceutical : Responds to Judgment in... [Published 4 Traders - Sep 10 2014]
Big Pharma's patent cliff losses spawn $239B sa... [Published FiercePharma - Sep 10 2014]
Diabetes belt puts the squeeze on US healthcare [Published Examiner.com - Sep 07 2014]
Pioglitazone post-marketing commitment, complet... [Published Orthopedics Today - Sep 06 2014]
Court Denies Lilly, Takeda’s Request to Toss $9... [Published FDA News - Sep 05 2014]
Japanese Government Prepares for Back Up Stimul... [Published Ticker - Sep 05 2014]
American Conference Institute's 19th Annual Dru... [Published Reed Smith LLP - Sep 05 2014]
No Bladder-Cancer Risk With Pioglitazone, Says ... [Published General Medicine eJournal - Sep 04 2014]
Takeda Pharmaceutical : U.S. court orders Taked... [Published 4 Traders - Sep 04 2014]
US court orders Takeda to pay punitive damages [Published NHK - Sep 04 2014]
Takeda Responds to Judgment in Diabetes Drug Case [Published Bio-Medicine - Sep 03 2014]
Takeda Responds to Judgment in Diabetes Drug Case [Published Securities Technology Monitor - Sep 03 2014]
Medicines update (18) [Published Pharmacy News - Sep 03 2014]
Mealey's PI/Product Liability - Actos MDL Judge... [Published Mealey - Sep 03 2014]
The Generic Drug Labeling Carve-Out Scorecard [Published FDA Law Blog - Sep 02 2014]
J&J’s Pinnacle Hips Face First Trial on Poisone... [Published Bloomberg - Sep 02 2014]
Takeda to submit data for pioglitazone containi... [Published Hospital Pharmacy Europe - Sep 01 2014]
Are Your Hormones Making You Miserable? [Published Huffington Post - Sep 01 2014]
Takeda announces long term pioglitazone study r... [Published Pharma Field - Sep 01 2014]
Takeda completes post-marketing commitment to s... [Published PBR - News - Sep 01 2014]
Long-term data show no cancer risk from Takeda/... [Published Pharma Times - Sep 01 2014]
Study calms pioglitazone bladder cancer concerns [Published 6minutes.net.au - Sep 01 2014]
Actos Lawsuit News: Federal Judge Won’t Dismiss... [Published PRWeb - Aug 31 2014]
Rx giants lose bid to avoid damages [Published Journal-Gazette - Aug 31 2014]
1 2 3 4 5 6
In Focus
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
Content Volume
Document Volume
Network
Network

Blogs

sort by: Date | Relevance
A Foregone Conclusion On A Runaway Verdict [Published Drug and Device Law - Sep 12 2014]
            From our ivory tower in the kingdom of blogdom, we track cases and litigations from afar, peeking in on them from decisions rendered at specific points in time.  Sometimes, from a single decision, we venture on what will happen next, like ...
The Generic Drug Labeling Carve-Out Scorecard [Published FDA Law Blog - Sep 02 2014]
By Kurt R. Karst –With the recent litigation surrounding FDA’s approval of ANDAs for generic versions of PRECEDEX (dexmedetomidine HCl) Injection – which litigation has now moved on to Motions for Summary Judgment (see our updates here for the latest ...
Takeda completes post-marketing commitment to s... [Published PBR - News - Sep 01 2014]
Takeda Pharmaceutical (Takeda) has completed the post-marketing commitment and submissions of data from a 10-year epidemiology study to regulatory authorities including the US Food and Drug Administration (FDA), the European Medicines Agency (EMA) and ...
No Actos Cancer Link in Long Term Data [Published MedPageToday.com - medical news plus CME for ph ... - Aug 29 2014]
(MedPage Today) -- Topline results from a 10-year analysis of diabetic patients treated with pioglitazone (Actos) indicated no increased risk of bladder cancer, even with long-term use, the drug's manufacturer said. ...
Takeda Announces Completion of the Post-Marketi... [Published PR Newswire: Health - Aug 28 2014]
OSAKA, Japan, Aug. 28, 2014 /PRNewswire/ -- Takeda Pharmaceutical Company Limited ("Takeda") today announced the completion of the post-marketing commitment and submissions of data from a 10-year epidemiology study to regulatory authorities including ...
1 2 3 4 5 6 7 8

Press Releases

sort by: Date | Relevance
Fitch: Lilly's Ratings Intact Following $9B Act... [Published Fitch Ratings Headlines Corporate - Apr 08 2014]
1
Contact Us
Sales
Support


Freebase CC-BY Some image thumbnails are sourced from Freebase, licensed under CC-BY

Copyright (C) 2014 Silobreaker Ltd. All rights reserved.
The selection and placement of stories and images on any Silobreaker page are determined automatically by a computer program.
The time or date displayed reflects when an article was added to or updated in Silobreaker.